List view / Grid view

Boehringer Ingelheim

 

news

Jentadueto® tablets receive approval for the treatment of adults with Type 2 Diabetes in Europe

25 July 2012 | By Boehringer Ingelheim

Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) received Marketing Authorisation from the European Commission for Jentadueto® which combines the DPP-4 inhibitor, linagliptin and metformin in a single tablet. 1 Linagliptin/metformin hydrochloride (HCl) will provide a new, single-tablet treatment option, taken twice-daily, for adults with Type 2 Diabetes. 1